Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
Improvements in inspiratory capacity with tiotropium in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide Source: International Congress 2015 – COPD: interesting notes Year: 2015
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
The effect of long-term administration of inhaled formoterol on VO2 max of COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 322s Year: 2004